DORGIO 7 ER DOWNLOAD

Type 2 diabetic patients Baseline SCr greater than 1. Pyridorin has a benign safety profile with the possible exception of a numerical increase in diarrhea and constipation with the higher dose of mg BID Pyridorin Safety Profile: Summer ; End trial: Jul ; 82 1 , J. With time to the composite endpoint consisting of the earliest event amongst: Year-one SCr change Dose: Evaluate Pyridorin mg twice daily BID efficacy compared to placebo in reducing the rate of progression of renal disease due to type 2 diabetes mellitus.

Uploader:	Nimuro
Date Added:	6 November 2016
File Size:	22.82 Mb
Operating Systems:	Windows NT/2000/XP/2003/2003/7/8/10 MacOS 10/X
Downloads:	94347
Price:	Free* [*Free Regsitration Required]

SCr change from baseline Dose: Jul ; 82 1J.

Pyridorin has a benign safety profile with the possible exception of a numerical increase in diarrhea and constipation with the higher dose of mg BID Pyridorin Safety Profile: With time to the composite endpoint consisting of the earliest event amongst: No composition of matter claim since this molecule already exists in the human body in microscopic quantities U.

Year-one SCr change Dose: Type 2 diabetic patients Baseline SCr greater than 1. Type 2 diabetes with overt nephropathy Baseline SCr: Prevention or slowing the progression of diabetic nephropathy with type 2 diabetes Program: Targeting the metabolic component of diabetic nephropathy.

Corporate Presentation September Two identical, double-blind Phase 3 studies of patients each Regulatory Agreements: In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this presentation, they may not be predictive of results or developments in future periods.

Any forward-looking statements that we make in this presentation speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this presentation, except as required vorgio law.

Evaluate safety and efficacy of Pyridorin at a mg twice daily dose compared to placebo to reduce the rate of renal disease progression due to type 2 diabetes mellitus Patient Population: Summer ; End trial: As diabetic nephropathy progresses, urinary TGFb values increase. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated.

Evaluate Pyridorin mg twice daily BID efficacy compared to placebo in reducing the rate of progression of renal disease due to type 2 diabetes mellitus.